PMID- 21466545
OWN - NLM
STAT- MEDLINE
DCOM- 20110520
LR  - 20211020
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Print)
IS  - 0009-9104 (Linking)
VI  - 164 Suppl 2
IP  - Suppl 2
DP  - 2011 Jun
TI  - Intravenous immunoglobulins in immunodeficiencies: more than mere replacement 
      therapy.
PG  - 2-5
LID - 10.1111/j.1365-2249.2011.04387.x [doi]
AB  - Intravenous immunoglobulin (IVIG) is a therapeutic compound prepared from pools 
      of plasma obtained from several thousand healthy blood donors. For more than 20 
      years, IVIG has been used in the treatment of a wide range of primary and 
      secondary immunodeficiencies. IVIG now represents a standard therapeutic option 
      for most antibody deficiencies. Routinely, IVIG is used in patients with X-linked 
      agammaglobulinaemia (XLA), common variable immunodeficiency (CVID), X-linked 
      hyper-IgM, severe combined immunodeficiency, Wiskott-Aldrich syndrome, and 
      selective IgG class deficiency. In addition, IVIG is used extensively in the 
      treatment of a wide variety of autoimmune disorders. IVIG is administered at 
      distinct doses in the two clinical settings: whereas immunodeficient patients are 
      treated with replacement levels of IVIG, patients with autoimmune and 
      inflammatory diseases are administered with very high doses of IVIG. Several 
      lines of experimental evidence gathered in the recent years suggest that the 
      therapeutic beneficial effect of IVIG in immunodeficiencies reflects an active 
      role for IVIG, rather than a mere passive transfer of antibodies.
CI  - (c) 2011 The Authors. Clinical and Experimental Immunology (c) 2011 British Society 
      for Immunology.
FAU - Kaveri, S V
AU  - Kaveri SV
AD  - Institut National de la Sante et de la Recherche Medicale Unite 872, Paris, 
      France. srini.kaveri@crc.jussieu.fr
FAU - Maddur, M S
AU  - Maddur MS
FAU - Hegde, P
AU  - Hegde P
FAU - Lacroix-Desmazes, S
AU  - Lacroix-Desmazes S
FAU - Bayry, J
AU  - Bayry J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Autoimmune Diseases/drug therapy
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Immunologic Deficiency Syndromes/*drug therapy
MH  - Treatment Outcome
PMC - PMC3087903
EDAT- 2011/04/16 06:00
MHDA- 2011/05/21 06:00
PMCR- 2012/06/01
CRDT- 2011/04/07 06:00
PHST- 2011/04/07 06:00 [entrez]
PHST- 2011/04/16 06:00 [pubmed]
PHST- 2011/05/21 06:00 [medline]
PHST- 2012/06/01 00:00 [pmc-release]
AID - 10.1111/j.1365-2249.2011.04387.x [doi]
PST - ppublish
SO  - Clin Exp Immunol. 2011 Jun;164 Suppl 2(Suppl 2):2-5. doi: 
      10.1111/j.1365-2249.2011.04387.x.